- Home
- GILD vs SAN Comparison
GILD vs SAN Comparison
Compare GILD & SAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- SAN
- Stock Information
- Founded
- GILD 1987
- SAN 1857
- Country
- GILD United States
- SAN Spain
- Employees
- GILD N/A
- SAN N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- SAN Commercial Banks
- Sector
- GILD Health Care
- SAN Finance
- Exchange
- GILD Nasdaq
- SAN Nasdaq
- Market Cap
- GILD 133.3B
- SAN 118.9B
- IPO Year
- GILD 1992
- SAN 1987
- Fundamental
- Price
- GILD $111.63
- SAN $8.32
- Analyst Decision
- GILD Buy
- SAN Strong Buy
- Analyst Count
- GILD 25
- SAN 1
- Target Price
- GILD $110.17
- SAN N/A
- AVG Volume (30 Days)
- GILD 8.9M
- SAN 7.1M
- Earning Date
- GILD 08-07-2025
- SAN 07-23-2025
- Dividend Yield
- GILD 2.83%
- SAN 2.04%
- EPS Growth
- GILD 1118.07
- SAN 20.30
- EPS
- GILD 4.73
- SAN 0.87
- Revenue
- GILD $28,735,000,000.00
- SAN $54,835,711,180.00
- Revenue This Year
- GILD $1.59
- SAN $23.44
- Revenue Next Year
- GILD $3.67
- SAN $2.47
- P/E Ratio
- GILD $23.62
- SAN $9.46
- Revenue Growth
- GILD 4.68
- SAN 6.36
- 52 Week Low
- GILD $66.01
- SAN $4.27
- 52 Week High
- GILD $119.96
- SAN $8.39
- Technical
- Relative Strength Index (RSI)
- GILD 58.05
- SAN 58.68
- Support Level
- GILD $104.46
- SAN $8.02
- Resistance Level
- GILD $112.00
- SAN $8.30
- Average True Range (ATR)
- GILD 2.78
- SAN 0.13
- MACD
- GILD 0.05
- SAN -0.00
- Stochastic Oscillator
- GILD 89.70
- SAN 77.68
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About SAN Banco Santander S.A. Sponsored ADR (Spain)
Santander's focus is on retail and commercial banking. Latin America is geographically the most significant operation, with Brazil making the largest contribution. Its continental European business is mainly in Spain and Portugal. Santander's UK presence is the result of its acquisition of Abbey building society. In the US, Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.